Analysen viste, at de kovarianter, som påvirkede clearance af erlotinib hos patienter fra pancreasstudiet var meget lig med dem, som blev set i den tidligere enkeltstof- farmakokinetiske analyse.
This analysis demonstrated that covariants affecting erlotinib clearance in patients from the pancreatic study were very similar to those seen in the prior single agent pharmacokinetic analysis.